Stay updated on Margetuximab Clinical Trial
Sign up to get notified when there's something new on the Margetuximab Clinical Trial page.

Latest updates to the Margetuximab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about the Expanded Access program for margetuximab in treating HER2-positive breast cancer, while a new version number has been added.SummaryDifference14%
- Check42 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 14, 2025.SummaryDifference1.0%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference3%
- Check93 days agoChange DetectedThe page has transitioned from MacroGenics to TerSera Therapeutics LLC as the entity responsible for considering requests for expanded access to margetuximab, with updated dates reflecting this change.SummaryDifference3%
- Check100 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference3%
Stay in the know with updates to Margetuximab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab Clinical Trial page.